Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy

Ann Transl Med. 2016 Feb;4(4):66. doi: 10.3978/j.issn.2305-5839.2015.10.40.

Authors

Yusuke Takahashi¹, Takashi Eguchi¹, Sarina Bains¹, Prasad S Adusumilli¹

Affiliation

¹ 1 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA ; 2 Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan ; 3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

PMID: 27004213
PMCID: PMC4779772
DOI: 10.3978/j.issn.2305-5839.2015.10.40

No abstract available

Grants and funding